Abstract
Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have